During preparation of this manuscript, several papers emerged reporting identification of somatic and germline mutations in the TERT promoter in a range of tumour types and cell lines including melanoma, glioma, hepatocellular carcinoma and others [23]–[25]. This evidence concerns the gene TERT and neoplasm.